Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

This study has been terminated.
(Majority of subjects who enrolled in the extension of the study had received on average 12 months of treatment.)
Elan Pharmaceuticals
Information provided by:
Biogen Idec Identifier:
First received: January 26, 2010
Last updated: September 12, 2013
Last verified: September 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: April 2012
  Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)